Back to Search
Start Over
Advances in the treatment of metastatic colorectal cancer
- Source :
- Clinical colorectal cancer. 1(1)
- Publication Year :
- 2002
-
Abstract
- Colorectal cancer represents the third leading cause of cancer mortality in the United States. During the past four decades, 5-fluorouracil (5-FU) has served as the cornerstone of therapy for individuals with advanced colorectal cancer (ACRC). Despite numerous attempts at maximizing efficacy of 5-FU through biochemical modulation, a significant benefit in terms of survival has never been realized. The recent emergence of novel chemotherapeutic drugs employing different mechanisms of action than 5-FU has led to the incorporation of irinotecan (CPT-11) with 5-FU/leucovorin as the new standard first-line regimen for future trials. This review outlines emerging data utilizing oral fluoropyrimidines and other new agents including oxaliplatin, raltitrexed, and eniluracil. Randomized clinical trials are currently underway in an effort to define optimal combination chemotherapy regimens, scheduling of agents, duration of therapy, and choice of therapy using a variety of prognostic molecular markers.
- Subjects :
- Oncology
medicine.medical_specialty
Organoplatinum Compounds
Colorectal cancer
medicine.medical_treatment
Administration, Oral
Antineoplastic Agents
Thiophenes
Irinotecan
Cancer Vaccines
Deoxycytidine
Drug Administration Schedule
law.invention
Capecitabine
Randomized controlled trial
law
Internal medicine
medicine
Humans
Prodrugs
Neoplasm Metastasis
Uracil
Randomized Controlled Trials as Topic
Chemotherapy
business.industry
Liver Neoplasms
Gastroenterology
Antibodies, Monoclonal
medicine.disease
Oxaliplatin
Regimen
Quinazolines
Camptothecin
Fluorouracil
business
Colorectal Neoplasms
Raltitrexed
medicine.drug
Subjects
Details
- ISSN :
- 15330028
- Volume :
- 1
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Clinical colorectal cancer
- Accession number :
- edsair.doi.dedup.....8e63b47eb2850fbe51e7c3555242a6cb